Annalisa Jenkins, MBBS, FRCP
Chief Executive Officer
Dr. Annalisa Jenkins, MBBS, FRCP is the chief executive officer of Dimension. A biopharma thought leader with nearly 20 years of industry experience, Dr. Jenkins has built and led teams advancing programs from scientific research through clinical development, regulatory approval and into healthcare systems globally. / Read more +
Prior to joining Dimension, Dr. Jenkins served as executive vice president, head of Global Research and Development for Merck Serono. She also led Global Medical Affairs and Quality and was a member of Merck Serono’s Pharmaceutical Executive Committee. Previously, Dr. Jenkins pursued a nearly 15-year career at Bristol-Myers Squibb (BMS), attaining the role of senior vice president and head of Global Medical Affairs. She began her career as a medical officer with the British Royal Navy during the Gulf conflict, rising to the rank of Surgeon Lieutenant Commander. Dr. Jenkins graduated in medicine from St. Bartholomew’s Hospital London and trained in cardiovascular medicine in the UK National Health Service.
Dr. Jenkins is a member of the board of directors of Ardelyx, Inc., Biothera Pharmaceutical Inc., iOX Therapeutics Limited, MedCity and Vium (elected to Executive Chair in 2017) and previously served as a board member of Prosensa Holding N.V. (acquired by BioMarin Pharmaceutical) and Viventia Bio, Inc. (acquired by Eleven Bio). She also is a committee member of the Science Board to the FDA, serves on the board of the Center for Talent Innovation (U.K.) and is on the Advisory Panel of the Healthcare Businesswomen’s Association.
Sam Wadsworth, PhD
Chief Scientific Officer
Dr. Wadsworth brings extensive drug discovery and development experience in the gene therapy and rare disease area. In his more than 20 years of industry experience at Genzyme and later Sanofi, he oversaw the discovery and translational research on multiple rare disease and gene therapy programs, including Genzyme’s only clinical stage gene therapy program./ Read more +
Most recently before joining Dimension, he served as the head of gene therapy research and early development at Sanofi Genzyme. Previously, he served as group vice president for translational research at Genzyme.
Dr. Wadsworth holds a Ph.D. from the University of Chicago and a B.A. from Southern Illinois University.
Chief Operating Officer
Ms. Thistle brings extensive experience in the life sciences industry, serving in senior finance, operations, and business development roles. Previously, Ms. Thistle was senior vice president, business development at Cubist Pharmaceuticals. / Read more +
Ms. Thistle received her B.A. degree in accounting from the University of Massachusetts.
Eric Crombez, MD
Chief Medical Officer
Dr. Crombez brings to Dimension extensive experience and expertise in the development and execution of clinical development programs for rare genetic disorders. / Read more +
Dr. Crombez obtained his B.S. degree in biology from the University of Michigan, Ann Arbor, and his M.D. degree from Wayne State University School of Medicine, Detroit. Dr. Crombez completed residencies in pediatrics and medical genetics and a fellowship in clinical biochemical genetics at the UCLA School of Medicine.
K. Reed Clark, PhD
Senior Vice President, Head of Pharmaceutical Development
Reed Clark, Ph.D. is a veteran molecular virologist and gene therapist with extensive experience in preclinical and translational adeno-associated virus (AAV) gene therapy studies. / Read more +
Dr. Clark received his B.S. in genetics and Ph.D. in molecular genetics from the Ohio State University, and was a post-doctoral fellow in gene therapy at Nationwide Children’s Hospital.
Alex Fotopoulos, MSc, MBA
Senior Vice President, Head of Technical Operations
Mr. Alex Fotopoulos brings to this role over 24 years of experience in global manufacturing and quality operations, biologics facilities and engineering, and clinical and commercial scale CMC operations gained in a range of therapeutic areas. / Read more +
Mr. Alex Fotopoulos received his Diploma in chemical engineering at the National Technical University of Athens, his M.Sc. degree in chemical engineering from Tufts University, and his MBA degree from the F. W. Olin Graduate School of Business at Babson College.
Vice President, Finance
Mr. Gaffey brings nearly 20 years of experience building and managing financial teams in the life-sciences industry. / Read more +
Mr. Gaffey received his BS in Environmental Science from the University of Massachusetts Amherst and his MS in Accounting and MBA from Northeastern University.
Janet Rae, RAC
Head of Global Regulatory Affairs
Ms. Rae brings over 25 years of regulatory affairs experience in the biopharmaceutical industry, including extensive experience in leading the development of compounds for rare diseases. / Read more +
Ms. Rae received her B.A. degree in Business Administration from Gordon College and holds a Regulatory Affairs Certification from the Regulatory Affairs Professional Society.
Khandan Baradaran, PhD
Head of Quality
Khandan Baradaran, Ph.D. is Head of Quality at Dimension Therapeutics. Dr. Baradaran has extensive expertise in the areas of viral safety, gene therapy vector development, vaccine development and assay technologies./ Read more +
Dr. Baradaran received her B.A degree in Molecular Biology from Wellesley College and her Ph.D. in Virology from Harvard University.
Rachel Strauss, MA
Head of Human Resources
Rachel brings broad expertise in human resources, talent management and organizational development within the life sciences industry. Prior to Dimension, Rachel was an accomplished human resources consultant and operated as the human resources leader at several startup biotechnology and medical diagnostics organizations. / Read more +
Rachel holds a Master’s degree in Human Resources and Industrial Relations from the University of Illinois, Champaign-Urbana and a Bachelor’s degree in Psychology from the University of Massachusetts, Amherst.